According to a recent LinkedIn post from Perplexity, the company is forming a Health Advisory Board focused on improving the accuracy and safety of its health-related AI outputs. The post indicates this board will consist of physicians, researchers, and health technology leaders tasked with guiding evidence-based product decisions, content quality, and patient safety.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post emphasizes that clinical decision-making remains the responsibility of physicians and patients, positioning Perplexity’s AI tools as supportive rather than directive in healthcare interactions. For investors, this move suggests a strategic push into the high-stakes health information segment, where accuracy, regulatory scrutiny, and trust are critical differentiators.
By highlighting expert oversight and evidence-based guidance, the post implies Perplexity is attempting to mitigate clinical and reputational risk while enhancing the reliability of its health-related outputs. If successful, this approach could strengthen the company’s credibility with healthcare professionals and partners, potentially opening paths to enterprise health, payer, or provider integrations.
The initiative also signals ongoing investment in specialized governance structures around AI safety, which may become increasingly important as regulators and health systems evaluate AI vendors. Over time, such advisory frameworks could support premium pricing, differentiated product positioning, and deeper penetration into the broader digital health and medical information markets.